vs
Orchid Island Capital, Inc.(ORC)与PUMA BIOTECHNOLOGY, INC.(PBYI)财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是Orchid Island Capital, Inc.的2.0倍($75.5M vs $38.5M),Orchid Island Capital, Inc.同比增速更快(372.6% vs 27.7%),过去两年Orchid Island Capital, Inc.的营收复合增速更高(301.6% vs 31.3%)
Orchid Island Capital是一家总部设在美国的专业金融企业,以房地产投资信托的形式开展运营,主要投资机构类及非机构类住宅抵押贷款支持证券,深耕美国固定收益市场,致力于为投资者创造稳定的经风险调整后的长期回报。
彪马生物技术是一家公开上市的生物制药企业,总部位于美国加利福尼亚州洛杉矶,专注于创新药物研发相关业务,在生物制药领域开展研发与商业化运营。
ORC vs PBYI — 直观对比
营收规模更大
PBYI
是对方的2.0倍
$38.5M
营收增速更快
ORC
高出344.9%
27.7%
两年增速更快
ORC
近两年复合增速
31.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $38.5M | $75.5M |
| 净利润 | $103.4M | — |
| 毛利率 | — | 69.3% |
| 营业利润率 | — | 22.7% |
| 净利率 | 268.7% | — |
| 营收同比 | 372.6% | 27.7% |
| 净利润同比 | 1764.9% | — |
| 每股收益(稀释后) | — | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
ORC
PBYI
| Q4 25 | $38.5M | $75.5M | ||
| Q3 25 | $26.9M | $54.5M | ||
| Q2 25 | $23.2M | $52.4M | ||
| Q1 25 | $19.7M | $46.0M | ||
| Q4 24 | — | $59.1M | ||
| Q3 24 | $340.0K | $80.5M | ||
| Q2 24 | $-697.0K | $47.1M | ||
| Q1 24 | $-2.5M | $43.8M |
净利润
ORC
PBYI
| Q4 25 | $103.4M | — | ||
| Q3 25 | $72.1M | $8.8M | ||
| Q2 25 | $-33.6M | $5.9M | ||
| Q1 25 | $17.1M | $3.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $17.3M | $20.3M | ||
| Q2 24 | $-5.0M | $-4.5M | ||
| Q1 24 | $19.8M | $-4.8M |
毛利率
ORC
PBYI
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
营业利润率
ORC
PBYI
| Q4 25 | — | 22.7% | ||
| Q3 25 | — | 17.6% | ||
| Q2 25 | — | 12.7% | ||
| Q1 25 | — | 8.7% | ||
| Q4 24 | — | 22.6% | ||
| Q3 24 | — | 27.4% | ||
| Q2 24 | — | -4.6% | ||
| Q1 24 | — | -5.3% |
净利率
ORC
PBYI
| Q4 25 | 268.7% | — | ||
| Q3 25 | 267.8% | 16.2% | ||
| Q2 25 | -145.0% | 11.2% | ||
| Q1 25 | 86.9% | 6.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 5094.1% | 25.2% | ||
| Q2 24 | 714.3% | -9.6% | ||
| Q1 24 | -794.2% | -11.0% |
每股收益(稀释后)
ORC
PBYI
| Q4 25 | — | $0.26 | ||
| Q3 25 | — | $0.17 | ||
| Q2 25 | — | $0.12 | ||
| Q1 25 | — | $0.06 | ||
| Q4 24 | — | $0.40 | ||
| Q3 24 | — | $0.41 | ||
| Q2 24 | — | $-0.09 | ||
| Q1 24 | — | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $665.9M | $97.5M |
| 总债务越低越好 | — | $22.7M |
| 股东权益账面价值 | $1.4B | $130.3M |
| 总资产 | $11.7B | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势,按日历期对齐
现金及短期投资
ORC
PBYI
| Q4 25 | $665.9M | $97.5M | ||
| Q3 25 | $583.9M | $94.4M | ||
| Q2 25 | $440.8M | $96.0M | ||
| Q1 25 | $396.4M | $93.2M | ||
| Q4 24 | — | $101.0M | ||
| Q3 24 | $322.1M | $96.7M | ||
| Q2 24 | $241.0M | $96.8M | ||
| Q1 24 | $190.4M | $107.2M |
总债务
ORC
PBYI
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
股东权益
ORC
PBYI
| Q4 25 | $1.4B | $130.3M | ||
| Q3 25 | $1.1B | $115.3M | ||
| Q2 25 | $912.0M | $104.7M | ||
| Q1 25 | $855.9M | $97.1M | ||
| Q4 24 | — | $92.1M | ||
| Q3 24 | $656.0M | $71.1M | ||
| Q2 24 | $555.9M | $48.5M | ||
| Q1 24 | $481.6M | $51.0M |
总资产
ORC
PBYI
| Q4 25 | $11.7B | $216.3M | ||
| Q3 25 | $9.1B | $202.9M | ||
| Q2 25 | $7.6B | $194.9M | ||
| Q1 25 | $7.3B | $196.2M | ||
| Q4 24 | — | $213.3M | ||
| Q3 24 | $5.9B | $220.7M | ||
| Q2 24 | $4.9B | $205.0M | ||
| Q1 24 | $4.2B | $214.1M |
负债/权益比
ORC
PBYI
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $120.4M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | — | $14.4M |
| 自由现金流率自由现金流/营收 | — | 19.1% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | 1.16× | — |
| 过去12个月自由现金流最近4个季度 | — | $41.7M |
8季度趋势,按日历期对齐
经营现金流
ORC
PBYI
| Q4 25 | $120.4M | $14.4M | ||
| Q3 25 | $28.0M | $9.7M | ||
| Q2 25 | $18.4M | $14.1M | ||
| Q1 25 | $25.8M | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | $-14.8M | $11.0M | ||
| Q2 24 | $19.3M | $1.0M | ||
| Q1 24 | $45.0M | $11.2M |
自由现金流
ORC
PBYI
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M | ||
| Q1 24 | — | — |
自由现金流率
ORC
PBYI
| Q4 25 | — | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | — |
资本支出强度
ORC
PBYI
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
现金转化率
ORC
PBYI
| Q4 25 | 1.16× | — | ||
| Q3 25 | 0.39× | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | 1.51× | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.86× | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.28× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图